You are here

Long-Acting Insulin Analogue Garners FDA Approval

June 17, 2005 -- Princeton, NJ -- Novo Nordisk announced today that the US Food and Drug Administration (FDA) has granted marketing authorisation for Levemir®, the company's long-acting insulin analogue for the treatment of diabetes. With the US approval of Levemir®, Novo Nordisk is the only company in the US with a complete range of insulin analogues, encompassing rapid-acting NovoLog®, premixed NovoLog® Mix 70/30 and now also the long-acting analogue Levemir®.

"The US approval of Levemir® is an important event for Novo Nordisk in the US as it completes our portfolio of insulin analogues and thereby paves the way for continued expansion of our US diabetes care franchise," says Kåre Schultz, executive vice president and chief operating officer.

In addition to the US approval, Levemir® has already been approved for use in 37 countries, including the countries in the European Union. The product has been introduced in 11 European markets, with additional launches expected during the second half of 2005.

Levemir® is a soluble, long-acting basal human insulin analogue with a relatively flat action profile and prolonged duration of action of up to 24 hours. Levemir® is indicated for once or twice-daily subcutaneous administration in the treatment of adult patients with diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycaemia. Levemir® can be used as the basal component of basal-bolus therapy in type 1 and type 2 diabetes and as add-on therapy in people with type 2 diabetes who are inadequately controlled on oral antidiabetic agents. The file on use in paediatrics is under review with the FDA and a decision is expected before the end of 2005.

Novo Nordisk expects to introduce Levemir® in the US market within the next 12 months. The approval of Levemir® does not change Novo Nordisk's expectations for the financial results for 2005.

Source: Novo Nordisk

Recent Headlines

A new 'road map' might make it easier
Rationing, canceled treatments, and fearful patients
Your heart will thank you
Seems like the 2013 Guidelines are having an impact
Biomarker blood tests pick up subtle clues
Meeting 'zombie cells' along the way
Drug resistance in HIV patients has nearly tripled since 2001
New drug addresses bacterial resistance to standard therapy